Project Grant K08HL171885

Award Date 7/1/24
Completion Date 6/30/29
Dollars Obligated $173K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under CFDA Program 93.859 - Biomedical Research and Research Training, provides $819,166 to Albany Medical College to conduct research on the role of the endothelium (inner lining of blood vessels) in determining outcomes for critically ill patients. The research aims to better understand the endothelial signaling pathways and transcriptional responses that lead to organ dysfunction and long-term...
This $598,228 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to investigate the role of endoplasmic reticulum autophagy (ER-phagy) in the immune response during sepsis. The research team at the University of Illinois will use state-of-the-art methods to define the mechanisms by which ER-phagy regulates the NLRP3 inflammasome activation and cytokine release in macrophages, ultimately contributing to lung injury during...
This $305,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of a clinical decision support system (CDSS) called Sepsis FLO. The CDSS is designed to precisely guide blood volume diagnosis and treatment for sepsis patients. Key activities include: 1) Developing an alpha prototype of the CDSS through user-centered design; 2) Validating three functional...
SUSPECT TREAT ORGAN FAILURE PREVENT SEPSIS MORTALITY (STOP SEPSIS MORTALITY) - PROJECT SUMMARY/ABSTRACT DESPITE ENORMOUS INVESTMENTS IN RESEARCH OVER THE LAST 30 YEARS, PEDIATRIC SEPSIS REMAINS A LEADING CAUSE OF IN-HOSPITAL DEATH, PARTICULARLY IN UNDERSERVED AND MINORITIZED POPULATIONS. SEPSIS IS DEFINED AS RAPIDLY PROGRESSIVE, LIFE-THREATENING ORGAN DYSFUNCTION (OD) DUE TO AN IMMUNE DYSREGULATION AS A RESPONSE TO INFECTION. IN THE U.S. OVER 75,000 CHILDREN ARE ADMITTED FOR SEPSIS ANNUALLY WITH...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $174,960 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Regents of the University of Michigan to support a project titled "Developing and Evaluating a Personalized Approach to Initial Fluid Resuscitation in Patients with Hospital-Onset Sepsis." The key goals of the project are to: 1) understand the impact of initial fluid volume on outcomes in patients with hospital-onset sepsis through an...
ADVANCING PRECISION MEDICINE FOR ARDS AND SEPSIS - ABSTRACT: THE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND SEPSIS ARE COMMON CAUSES OF DEATH IN CRITICALLY ILL PATIENTS, YET BOTH ARE CLINICAL SYNDROMES DEFINED BY NON-SPECIFIC SIGNS AND SYMPTOMS WHICH ENCOMPASS MAJOR CLINICAL AND BIOLOGICAL HETEROGENEITY. PRE-CLINICAL STUDIES HAVE IDENTIFIED NUMEROUS PROMISING THERAPEUTIC AGENTS FOR BOTH ARDS AND SEPSIS, BUT CLINICAL TRIALS OF NOVEL PHARMACOTHERAPIES IN THESE SYNDROMES HAVE BEEN...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), with a total funding amount of $392,660, supports research to investigate the role of red blood cells and the toll-like receptor 7 (TLR7) in regulating the immune response during sepsis. The project, titled "Investigating the Function of RBC-TLR7 in Sepsis," aims to elucidate novel mechanisms of immune dysregulation in sepsis and enhance the understanding of how red blood cells contribute to the...
This federal Project Grant award, valued at $950,664.00 and awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the relationship between the gut microbiome and acute muscle loss in sepsis. The key objectives of this award are to: 1) Determine the interaction between gut microbiota and body composition in predicting clinical outcomes...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $322,480 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to define the role of endothelial sphingosine-1-phosphate receptor 1 (S1PR1) signaling in promoting lung repair and preventing pulmonary fibrosis after viral respiratory...

THE PHYSIOLOGY AND BIOCHEMISTRY OF SEPSIS-INDUCED VASOPLEGIA - PROJECT SUMMARY/ABSTRACT SEPSIS IS A COMPLEX, HETEROGENEOUS, GLOBAL INFLAMMATORY RESPONSE TO AN INFECTION THAT PRECIPITATES CRITICAL HYPOTENSION, IS BESET WITH HIGH MORTALITY, AND CONSTITUTES A CLINICAL EMERGENCY. LARGE BLOOD VESSELS (MACROVESSELS) BECOME ATONIC AND FLUID-PERMEABLE, WHILE SMALL VESSELS (MICROVASCULAR BEDS) DO NOT PERFUSE, CAUSING SHOCK AND HYPOXIC ORGAN DAMAGE, A CONDITION TERMED VASOPLEGIA. DR. WISE ENDEAVORS TO BECOME AN INDEPENDENTLY FUNDED, COLLABORATIVE SURGEON-SCIENTIST BY CHARACTERIZING PHYSIOLOGIC INJURY AND DEFINING CELLULAR PROCESSES THAT OCCUR DURING THE VASOPLEGIA PRECIPITATED BY SEPSIS. WHILE ELIMINATION OF THE INFECTIOUS PATHOGEN IS MOST CRITICAL TO SURVIVAL, MITIGATING VASOPLEGIC PHYSIOLOGY PREVENTS MORBIDITY TO VITAL END ORGANS SUCH AS THE LUNG. EXAMINING THE PROBLEM OF VASOPLEGIA FROM THE LENS OF THE VASCULAR SYSTEM NECESSARILY REQUIRES CAREER DEVELOPMENT IN THREE KEY AREAS, IDENTIFIED TO OPTIMALLY ADDRESS THE RESEARCH QUESTION: CELL BIOLOGY AND MULTI- OMICS, USE OF INTRAVITAL SURVEILLANCE TECHNIQUES (MICROSCOPY), AND FACILITY WITH LARGE ANIMAL MODELS TO BEST RECAPITULATE HUMAN PHYSIOLOGY IN SEPSIS. THIS PROJECT IS WELL-POSITIONED TO SUCCEED DUE TO A COMPLEMENTARY MENTORSHIP AND ADVISORY TEAM LED BY DR. GREG BEILMAN (UNIVERSITY OF MINNESOTA), STRONG INSTITUTIONAL SUPPORT, AND A FOCUSED CAREER DEVELOPMENT PLAN INCLUSIVE OF GERMANE COURSEWORK, DIDACTICS, SEMINARS AND MEETINGS. VASOPLEGIA WILL BE STUDIED USING A NEWLY-PILOTED PORCINE "FECAL CLOT" (WITH ISCHEMIA-REPERFUSION INJURY) MODEL OF SURGICALLY-INDUCED SEPSIS. IN THE FIRST AIM, FECAL CLOT SEPSIS OR "SHAM" SEPSIS WILL BE INDUCED, FOLLOWED BY SURGICAL HARVEST OF MESENTERIC AND SAPHENOUS ARTERIES AND VEINS AFTER 24 HOURS. CUT RINGS FROM THESE VESSELS WILL BE SUSPENDED IN A MUSCLE BATH TO DETERMINE RELATIVE SEVERITY OF INJURY OF SMOOTH MUSCLE CELLS, ENDOTHELIAL CELLS AND EXTRACELLULAR MATRIX. PERMEABILITY WILL BE ASSESSED VIA IMMUNOHISTOCHEMICAL STAINING FOR GLYCOCALYX. REGULATION OF THE ENDOPLASMIC RETICULUM STRESS RESPONSE AND P38 MAP KINASE ACTIVATION BY PUTATIVE ENDOGENOUS INHIBITOR NIBAN WILL BE STUDIED, TO ASSESS THE ROLE OF "OFF-SIGNALING" IN PROPAGATING SEPTIC INFLAMMATION. IN THE SECOND AIM, LUNG MICROVASCULATURE WILL BE IMAGED USING INTRAVITAL ORTHOGONAL POLARIZED SPECTRAL VIDEO-MICROSCOPY, TO QUANTIFY THE LOSS OF PERFUSED VESSELS AND BLOOD FLOW INDUCED BY FECAL CLOT SEPSIS. AFTER SYNTHESIS OF MACROVASCULAR AND MICROVASCULAR INJURY PATTERNS OF VASOPLEGIA FROM THE FIRST TWO AIMS, A PILOT MITIGATION STRATEGY WILL BE TESTED IN THE THIRD AIM. INTRAVENOUS "NIPP," A RATIONALLY DESIGNED CELL-PERMEANT PHOSPHO-MIMETIC OF NIBAN DEVELOPED IN THE LABORATORY OF COLLEEN BROPHY (CO-MENTOR), WILL BE ADMINISTERED TO SEPTIC PIGS, TO DECREASE HARMFUL "FEED-FORWARD" ACTIVATION OF INJURY-INDUCED PRO-INFLAMMATORY PATHWAYS LEADING TO VASOPLEGIA. THE PRIMARY OUTCOME WILL BE IMPROVEMENT IN A VALIDATED CLINICAL PORCINE SEPSIS SCORE. ALL PIGS WILL HAVE SYSTEMIC VASCULAR TISSUE EXTENSIVELY BIO-BANKED UPON EUTHANASIA. THE ROBUST ANIMAL MODEL, DATA TO BE COLLECTED, AND THE LEARNED RESEARCH TECHNIQUES WILL COLLECTIVELY PREDICATE A DYNAMIC RESEARCH PROGRAM, WITH POTENTIAL FOR TRANSLATING OUR FINDINGS TO ULTIMATELY IMPROVE SURVIVAL FROM SEPSIS, A MAJOR UNMET CLINICAL NEED.

Posted 6/29/24, 12:00 AM